UBS Maintains Buy on AnaptysBio, Raises Price Target to $90

Benzinga Newsdesk www.benzinga.com Positive 75.1%

Neg 0% Neu 0% Pos 75.1%

UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $70 to $90.

Comments

No comments yet. Be the first!